About Prolia® (denosumab) Prolia is approved in the U.S. for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Does Prolia cause aortic stenosis?
We found that denosumab and alendronate have no major effect on the progression of aortic stenosis as assessed by echocardiography, computed tomography, or 18F-sodium fluoride positron emission tomography.
What is a special precaution of denosumab?
Avoid being near people who are sick or have infections while you are receiving this medicine. Check with your doctor right away if you have a fever or chills, red, swollen skin, severe abdominal or stomach pain, or burning or painful urination. Skin problems may occur after receiving Prolia®.
How safe is denosumab?
Denosumab has proven effective at building bone density and reducing spine and hip fractures. However, it carries a risk of serious side effects. People with weakened immune systems are advised not to use to denosumab because it can lead to serious infections that require hospitalization (such as heart infections).
When was Denosumab Approved by FDA?
Development Timeline for Prolia
| Date | Article |
|---|---|
| Jun 1, 2010 | Approval FDA Approves Amgen’s Prolia (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture |
| May 17, 2010 | Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients |
When are bisphosphonates contraindicated?
Avoid oral bisphosphonates in patients with esophageal disorders such as achalasia, esophageal stricture, esophageal varices, Barrett’s esophagus, inability to stand or sit upright for at least 30 minutes, history of bariatric surgery (Roux-en-Y gastric bypass).
Does prolia cause calcium deposits?
Denosumab may cause low calcium levels, especially if you have kidney problems. Take calcium and vitamin D as directed by your doctor.
Is denosumab better than bisphosphonates?
Denosumab was superior to bisphosphonates for increasing bone mineral density (BMD), and possibly for reducing fracture risk, in patients with osteoporosis or low BMD, according to a report published in the Journal of Clinical Endocrinology & Metabolism.
Is denosumab an immunotherapy?
A type of immunotherapy drug called denosumab binds to a protein called RANKL, which may help keep bone from breaking down. This phase II trial studies how well denosumab works in decreasing breast density in premenopausal women with dense breasts who have a high risk of developing breast cancer.
Which problem may occur during therapy with denosumab?
The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. The most common adverse reactions reported with Prolia in men with osteoporosis are back pain, arthralgia, and nasopharyngitis.
FDA Approves New Indications for Prolia (denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy. Jun 1, 2010. FDA Approves Amgen’s Prolia (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture.
What should I know before taking denosumab 120 mg (duloxetine)?
A dental examination and appropriate preventive dentistry before starting denosumab 120 mg are now recommended for all patients. Do not start denosumab 120 mg in patients with a dental or jaw condition requiring surgery, or in patients who have not recovered following oral surgery. Check for ONJ risk factors before starting denosumab 60 mg.
What are the risk factors for osteoporosis in patients receiving denosumab 60 mg?
There have been rare cases of ONJ in patients receiving denosumab 60 mg for osteoporosis in clinical practice. The most common risk factors were invasive dental procedures, history of bisphosphonate therapy, and being more than 65 years old. To date, we have received 9 Yellow Card reports [1][1]…
What is the incidence of ONJ with denosumab 120 mg?
In clinical trials, ONJ incidence increased with duration of denosumab 120 mg exposure. The patient-year adjusted incidence of confirmed ONJ was 1.1% in the first year of treatment, 3.7% in the second year, and 4.6% per year thereafter.
